Annual FCF
$468.37 M
+$95.09 M+25.47%
December 31, 2024
Summary
- As of February 25, 2025, HALO annual free cash flow is $468.37 million, with the most recent change of +$95.09 million (+25.47%) on December 31, 2024.
- During the last 3 years, HALO annual FCF has risen by +$170.38 million (+57.18%).
- HALO annual FCF is now at all-time high.
Performance
HALO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
$175.41 M
+$61.56 M+54.06%
December 31, 2024
Summary
- As of February 25, 2025, HALO quarterly free cash flow is $175.41 million, with the most recent change of +$61.56 million (+54.06%) on December 31, 2024.
- Over the past year, HALO quarterly FCF has stayed the same.
- HALO quarterly FCF is now at all-time high.
Performance
HALO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
$468.37 M
+$75.66 M+19.27%
December 31, 2024
Summary
- As of February 25, 2025, HALO TTM free cash flow is $468.37 million, with the most recent change of +$75.66 million (+19.27%) on December 31, 2024.
- Over the past year, HALO TTM FCF has stayed the same.
- HALO TTM FCF is now at all-time high.
Performance
HALO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
HALO Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.5% | 0.0% | 0.0% |
| 3 y3 years | +57.2% | +35.5% | +32.5% |
| 5 y5 years | +623.5% | +35.5% | +32.5% |
HALO Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +99.0% | at high | +346.8% | at high | +99.0% |
| 5 y | 5-year | at high | +623.5% | at high | +743.4% | at high | +623.5% |
| alltime | all time | at high | +623.5% | at high | +671.5% | at high | +623.5% |
Halozyme Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $468.37 M(+25.5%) | $175.41 M(+54.1%) | $468.37 M(+19.3%) |
| Sep 2024 | - | $113.86 M(+114.0%) | $392.71 M(-3.8%) |
| Jun 2024 | - | $53.21 M(-57.7%) | $408.32 M(-3.6%) |
| Mar 2024 | - | $125.88 M(+26.2%) | $423.57 M(+13.5%) |
| Dec 2023 | $373.28 M(+58.6%) | $99.76 M(-22.9%) | $373.28 M(+5.6%) |
| Sep 2023 | - | $129.47 M(+89.1%) | $353.63 M(+20.8%) |
| Jun 2023 | - | $68.47 M(-9.4%) | $292.79 M(+11.1%) |
| Mar 2023 | - | $75.59 M(-5.6%) | $263.58 M(+12.0%) |
| Dec 2022 | $235.30 M(-21.0%) | $80.11 M(+16.7%) | $235.30 M(-0.9%) |
| Sep 2022 | - | $68.63 M(+74.8%) | $237.55 M(-18.1%) |
| Jun 2022 | - | $39.26 M(-17.0%) | $290.17 M(+1.0%) |
| Mar 2022 | - | $47.31 M(-42.6%) | $287.26 M(-3.6%) |
| Dec 2021 | $297.98 M(+462.8%) | $82.36 M(-32.1%) | $297.98 M(+12.5%) |
| Sep 2021 | - | $121.24 M(+233.5%) | $264.85 M(+77.1%) |
| Jun 2021 | - | $36.36 M(-37.3%) | $149.51 M(+29.0%) |
| Mar 2021 | - | $58.03 M(+17.9%) | $115.93 M(+118.9%) |
| Dec 2020 | $52.95 M(-159.2%) | $49.22 M(+733.1%) | $52.95 M(-325.0%) |
| Sep 2020 | - | $5.91 M(+112.6%) | -$23.54 M(-60.9%) |
| Jun 2020 | - | $2.78 M(-156.1%) | -$60.14 M(-32.5%) |
| Mar 2020 | - | -$4.96 M(-81.8%) | -$89.07 M(-0.4%) |
| Dec 2019 | -$89.46 M(+65.2%) | -$27.27 M(-11.2%) | -$89.46 M(+63.2%) |
| Sep 2019 | - | -$30.69 M(+17.4%) | -$54.81 M(+26.4%) |
| Jun 2019 | - | -$26.15 M(+388.8%) | -$43.38 M(+18.8%) |
| Mar 2019 | - | -$5.35 M(-172.4%) | -$36.50 M(-32.6%) |
| Dec 2018 | -$54.16 M(-140.8%) | $7.39 M(-138.4%) | -$54.16 M(-159.6%) |
| Sep 2018 | - | -$19.26 M(-0.1%) | $90.84 M(-30.2%) |
| Jun 2018 | - | -$19.28 M(-16.2%) | $130.19 M(-1.6%) |
| Mar 2018 | - | -$23.02 M(-115.1%) | $132.25 M(-0.3%) |
| Dec 2017 | $132.70 M(-348.0%) | $152.39 M(+658.2%) | $132.70 M(-469.6%) |
| Sep 2017 | - | $20.10 M(-216.7%) | -$35.90 M(-44.9%) |
| Jun 2017 | - | -$17.23 M(-23.6%) | -$65.17 M(+5.2%) |
| Mar 2017 | - | -$22.56 M(+39.1%) | -$61.96 M(+15.8%) |
| Dec 2016 | -$53.52 M(+35.7%) | -$16.21 M(+76.8%) | -$53.52 M(-1.1%) |
| Sep 2016 | - | -$9.17 M(-34.5%) | -$54.14 M(-13.1%) |
| Jun 2016 | - | -$14.01 M(-0.8%) | -$62.29 M(+57.3%) |
| Mar 2016 | - | -$14.12 M(-16.1%) | -$39.60 M(+0.4%) |
| Dec 2015 | -$39.44 M(-19.3%) | -$16.83 M(-2.8%) | -$39.44 M(+65.8%) |
| Sep 2015 | - | -$17.32 M(-299.6%) | -$23.79 M(+18.8%) |
| Jun 2015 | - | $8.68 M(-162.1%) | -$20.02 M(-55.3%) |
| Mar 2015 | - | -$13.97 M(+1088.9%) | -$44.81 M(-8.3%) |
| Dec 2014 | -$48.89 M(-5.3%) | -$1.18 M(-91.3%) | -$48.89 M(-24.0%) |
| Sep 2014 | - | -$13.55 M(-15.9%) | -$64.29 M(+1.3%) |
| Jun 2014 | - | -$16.12 M(-10.7%) | -$63.47 M(+8.7%) |
| Mar 2014 | - | -$18.04 M(+8.8%) | -$58.39 M(+13.1%) |
| Dec 2013 | -$51.64 M | -$16.58 M(+30.1%) | -$51.64 M(-1.6%) |
| Sep 2013 | - | -$12.74 M(+15.4%) | -$52.47 M(-3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2013 | - | -$11.04 M(-2.2%) | -$54.19 M(-5.9%) |
| Mar 2013 | - | -$11.28 M(-35.2%) | -$57.62 M(-12.3%) |
| Dec 2012 | -$65.69 M(+87.0%) | -$17.41 M(+20.3%) | -$65.69 M(+5.4%) |
| Sep 2012 | - | -$14.47 M(+0.0%) | -$62.34 M(+1.6%) |
| Jun 2012 | - | -$14.46 M(-25.3%) | -$61.36 M(+42.1%) |
| Mar 2012 | - | -$19.36 M(+37.7%) | -$43.19 M(+23.0%) |
| Dec 2011 | -$35.13 M(-23.7%) | -$14.06 M(+4.3%) | -$35.13 M(+22.1%) |
| Sep 2011 | - | -$13.48 M(-463.5%) | -$28.77 M(+6.7%) |
| Jun 2011 | - | $3.71 M(-132.8%) | -$26.97 M(-39.5%) |
| Mar 2011 | - | -$11.30 M(+46.6%) | -$44.58 M(-3.2%) |
| Dec 2010 | -$46.03 M(+10.6%) | -$7.71 M(-34.0%) | -$46.03 M(-7.7%) |
| Sep 2010 | - | -$11.68 M(-16.0%) | -$49.86 M(-5.6%) |
| Jun 2010 | - | -$13.90 M(+9.0%) | -$52.81 M(+5.1%) |
| Mar 2010 | - | -$12.75 M(+10.6%) | -$50.26 M(+20.8%) |
| Dec 2009 | -$41.61 M(+13.9%) | -$11.53 M(-21.2%) | -$41.61 M(+5.7%) |
| Sep 2009 | - | -$14.63 M(+29.0%) | -$39.37 M(+10.0%) |
| Jun 2009 | - | -$11.35 M(+176.8%) | -$35.80 M(+2.5%) |
| Mar 2009 | - | -$4.10 M(-55.9%) | -$34.92 M(-4.4%) |
| Dec 2008 | -$36.53 M(+1353.8%) | -$9.29 M(-16.0%) | -$36.53 M(+3.1%) |
| Sep 2008 | - | -$11.06 M(+5.7%) | -$35.45 M(+74.4%) |
| Jun 2008 | - | -$10.47 M(+83.2%) | -$20.32 M(+42.7%) |
| Mar 2008 | - | -$5.71 M(-30.4%) | -$14.24 M(+466.8%) |
| Dec 2007 | -$2.51 M(-137.4%) | -$8.21 M(-301.9%) | -$2.51 M(-111.6%) |
| Sep 2007 | - | $4.07 M(-192.7%) | $21.74 M(+47.7%) |
| Jun 2007 | - | -$4.39 M(-172.9%) | $14.72 M(-5.5%) |
| Mar 2007 | - | $6.02 M(-62.5%) | $15.57 M(+131.9%) |
| Dec 2006 | $6.71 M(-150.3%) | $16.05 M(-643.1%) | $6.71 M(-151.9%) |
| Sep 2006 | - | -$2.95 M(-16.5%) | -$12.94 M(-3.9%) |
| Jun 2006 | - | -$3.54 M(+24.5%) | -$13.46 M(+3.6%) |
| Mar 2006 | - | -$2.84 M(-21.3%) | -$13.00 M(-2.6%) |
| Dec 2005 | -$13.35 M(+68.0%) | -$3.61 M(+3.9%) | -$13.35 M(+5.4%) |
| Sep 2005 | - | -$3.48 M(+13.1%) | -$12.66 M(+7.8%) |
| Jun 2005 | - | -$3.07 M(-3.6%) | -$11.74 M(+15.0%) |
| Mar 2005 | - | -$3.19 M(+9.1%) | -$10.21 M(+28.5%) |
| Dec 2004 | -$7.95 M(>+9900.0%) | -$2.92 M(+14.2%) | -$7.95 M(+95.6%) |
| Sep 2004 | - | -$2.56 M(+65.8%) | -$4.06 M(+156.3%) |
| Jun 2004 | - | -$1.54 M(+67.5%) | -$1.59 M(-121.8%) |
| Mar 2004 | - | -$920.90 K(-195.9%) | $7.26 M(<-9900.0%) |
| Dec 2003 | -$49.70 K(-10.9%) | $960.40 K(-1275.5%) | -$49.70 K(-95.3%) |
| Sep 2003 | - | -$81.70 K(-101.1%) | -$1.05 M(+7.3%) |
| Jun 2003 | - | $7.30 M(-188.7%) | -$978.40 K(-88.2%) |
| Mar 2003 | - | -$8.23 M(>+9900.0%) | -$8.27 M(>+9900.0%) |
| Dec 2002 | -$55.80 K(+62.2%) | -$39.50 K(+276.2%) | -$55.70 K(+243.8%) |
| Sep 2002 | - | -$10.50 K(-252.2%) | -$16.20 K(+184.2%) |
| Jun 2002 | - | $6900.00(-154.8%) | -$5700.00(-54.8%) |
| Mar 2002 | - | -$12.60 K | -$12.60 K |
| Dec 2001 | -$34.40 K | - | - |
FAQ
- What is Halozyme Therapeutics annual free cash flow?
- What is the all time high annual FCF for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual FCF year-on-year change?
- What is Halozyme Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly FCF year-on-year change?
- What is Halozyme Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Halozyme Therapeutics?
- What is Halozyme Therapeutics TTM FCF year-on-year change?
What is Halozyme Therapeutics annual free cash flow?
The current annual FCF of HALO is $468.37 M
What is the all time high annual FCF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual free cash flow is $468.37 M
What is Halozyme Therapeutics annual FCF year-on-year change?
Over the past year, HALO annual free cash flow has changed by +$95.09 M (+25.47%)
What is Halozyme Therapeutics quarterly free cash flow?
The current quarterly FCF of HALO is $175.41 M
What is the all time high quarterly FCF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly free cash flow is $175.41 M
What is Halozyme Therapeutics quarterly FCF year-on-year change?
Over the past year, HALO quarterly free cash flow has changed by $0.00 (0.00%)
What is Halozyme Therapeutics TTM free cash flow?
The current TTM FCF of HALO is $468.37 M
What is the all time high TTM FCF for Halozyme Therapeutics?
Halozyme Therapeutics all-time high TTM free cash flow is $468.37 M
What is Halozyme Therapeutics TTM FCF year-on-year change?
Over the past year, HALO TTM free cash flow has changed by $0.00 (0.00%)